Model N MODN dropped 31.57% to $10.08 on downbeat FY14 forecast. JP Morgan downgraded the stock from “overweight” to “neutral.”
Neurocrine Biosciences NBIX plummeted 29.82% to $11.72 after the company reported Phase IIb results Of VMAT2 Inhibitor NBI-98854 for treatment of tardive dyskinesia.
ChemoCentryx CCXI dropped 23.97% to $6.28 after the company announced top-line interim results for CCX140 in an ongoing Phase II trial.
HD Supply Holdings HDS dropped 11.59% to $21.88 on Q2 results.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in